Lataa...
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the...
Tallennettuna:
| Julkaisussa: | Diabetes Metab Syndr Obes |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485795/ https://ncbi.nlm.nih.gov/pubmed/26150733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S69282 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|